The long and winding road of the clinical development of Nelarabine

Leukemia and Lymphoma

Volumn 48, Issue 1, 2007, Pages 1-2

  Kurtzberg, Joanne ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE ARABINOSIDE; NELARABINE; PURINE NUCLEOSIDE PHOSPHORYLASE; ARABINONUCLEOSIDE;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; COMA; DOSE RESPONSE; DRUG APPROVAL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG SOLUBILITY; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PARALYSIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SEIZURE; SOMNOLENCE; T CELL LEUKEMIA; T CELL LYMPHOMA; TOXICITY TESTING; ADULT; CHILD;

ADULT; ARABINONUCLEOSIDES; CHILD; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA, T-CELL;

EID: 34247261009     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601135447     Document Type: Note

References (9)

1. Czuczman, M., Porcu, P., Johnson, J., Niedzwiecki, D., Kelly, M. and Hsi, E. (2006) Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. J Leuk Lymphoma, 48, pp. 97-103.
2. Kurtzberg, J., Ernst, T. J., Keating, M. J., Gandhi, V., Hodge, J. P. and Kisor, D. F. (2005) Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol, 23, pp. 3396-3403.
3. Kisor, D. F., Plunkett, W., Kurtzberg, J., Mitchell, B., Hodge, J. P. and Ernst, T. (2000) Pharmacokinetics of nelarabine and 9-Beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol, 18, pp. 995-1003.
4. Berg, S. L., Blaney, S. M., Devidas, M., Lampkin, T. A., Murgo, A. and Bernstein, M. (2005) Phase II Study of nelarabine (compound 506u78) in children and young adults with refractory t-cell malignancies: A report from the children's oncology group. J Clin Oncol, 23, pp. 3376-3382.
5. Gandhi, V., Plunkett, W., Rodriguez Jr, C. O., Nowak, B. J. and Ayres, M. (1998) Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol, 16, pp. 3607-3615.
6. Giblett, E., Ammann, A., Wara, D., Sandman, R. and Diamond, L. (1975) Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet, 1, pp. 1010-1013.
7. Cohen, A., Gudas, L. and Ammann, A. (1978) Deoxyguanosine triphosphate, a possible toxic metabolite in immunodeficiency associated with purine nuclotide phosphorylase deficiency. J Clin Invest, 61, pp. 1405-1410.
8. Gravatt, L. C., Chaffee, S., Hebert, M. E., Halperin, E. C., Friedman, H. S. and Kurtzberg, J. (1993) Efficacy and toxicity of 9-Beta-D-arabinofuranosylguanine (araG) as an agent to purge malignant T cells from murine bone marrow: Application to an in vivo T-leukemia model. Leukemia, 7, pp. 1261-1267.
9. Hebert, M. E., Greenberg, M. L., Chaffee, S., Gravatt, L., Hershfield, M. S. and Elion, G. B. (1991) Pharmacologic purging of malignant T cells from human bone marrow using 9-Beta-D-arabinofuranosylguanine. Transplantation, 52, pp. 634-640.